Pulse Biosciences (PLSE) Current Deferred Revenue (2017 - 2023)

Pulse Biosciences' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $4000.0 for Q1 2023.

• In Q1 2023, Current Deferred Revenue fell 75.0% year-over-year to $4000.0; the TTM figure through Mar 2023 stood at $4000.0 (down 75.0% YoY), while the FY2021 annual figure was $16000.0, changed N/A from the prior year.
• Current Deferred Revenue was $4000.0 for Q1 2023 at Pulse Biosciences, down from $38000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $38000.0 in Q3 2022 to a low of $4000.0 in Q1 2023.
• Historically, Current Deferred Revenue has averaged $18833.3 across 3 years, with a median of $16000.0 in 2021.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue jumped 442.86% in 2022, then sank 75.0% in 2023.
• A 3-year view of Current Deferred Revenue shows it stood at $16000.0 in 2021, then surged by 137.5% to $38000.0 in 2022, then plunged by 89.47% to $4000.0 in 2023.
• The last three Current Deferred Revenue figures came in at $4000.0 (Q1 2023), $38000.0 (Q3 2022), and $32000.0 (Q2 2022), per Business Quant data.